TrialCancer research and treatment2022

Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer.

Yong-Pyo Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.